每经AI快讯，ST葫芦娃（SH 605199，收盘价：8.62元）12月15日晚间发布公告称，公司第四届2025年 第三次董事会临时会议于2025年12月15日在海南省海口市秀英区安读一路30号公司会议室以现场结合通 讯方式召开。会议审议了《关于聘任2025年度会计师事务所的议案》等文件。 每经头条（nbdtoutiao）——中标企业频频弃标 大型医疗设备采购有何难言之隐？ （记者 王晓波） 2024年1至12月份，ST葫芦娃的营业收入构成为：医药制造业占比100.0%。 截至发稿，ST葫芦娃市值为34亿元。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-089 海南葫芦娃药业集团股份有限公司 第四届董事会 2025 年第三次临时会议决议公告 表决结果：同意 7 票，弃权 0 票，反对 0 票。 本议案已经公司董事会审计委员会审议通过并同意提交公司董事会审议。 （二）审议通过了《关于提请召开 2025 年第三次临时股东大会的议案》 （一）海南葫芦娃药业集团股份有限公司（以下简称"公司"）第四届董事会 2025 年第三次临时会议的召开符合《公司法》《公司章程》和《董事会议事规则》的有关 规定，会议合法有效。 （二）会议通知于 2025 年 12 月 11 日以通讯方式发出。 （三）会议于 2025 年 12 月 15 日在海南省海口市秀英区安读一路 30 号公司会 议室以现场结合通讯方式召开。 （四）公司董事会会议应出席董事 7 人，实际出席董事 7 人（其中以通讯表决 方式出席会议的董事 2 人）。 （五）本次董事会会议由董事长刘景萍女士主 ...

Group 1 - The flu activity in China is on the rise, with a peak expected between mid-December and early January, leading to increased demand for antiviral and symptomatic treatment drugs, especially among children [1] - Bank securities report indicates that antiviral drugs are the main treatment method, with good expected efficacy; various traditional Chinese medicines and antipyretics are also available to alleviate symptoms during the illness [1] - Data from Meituan shows that since November, the overall order volume for specific flu medications has increased by over 100%, with orders for Oseltamivir granules rising by over 85% and for Baloxavir increasing by over 110% [1] Group 2 - Hainan Huhuwawa Pharmaceutical Group's Oseltamivir products have performed well, with capsules approved for production and stable market supply for the prevention and treatment of influenza A and B [3] - The company has developed a dry suspension that received drug registration certification in September, addressing dosage challenges for young children aged two and above [3] - The core product, Pediatric Lung Heat Cough and Asthma Granules, has been included in national treatment guidelines and health insurance directories, enhancing its market presence [3] Group 3 - Huhuwawa Pharmaceutical emphasizes research and innovation as a core driver for development, continuously enhancing R&D efforts in the pediatric medication sector [4] - The company has increased investment in R&D for pediatric drugs, with ongoing projects targeting infectious diseases, functional dyspepsia, allergic diseases, and adenoid hypertrophy [4]

Core Viewpoint - ST HULUWAWA (605199) announced that its controlling shareholder, Hainan Huluwawa Investment Development Co., Ltd., has had 23.9 million shares judicially frozen, representing 14.3% of its holdings and 5.97% of the company's total share capital [1] Group 1 - The freezing period for the shares is from December 5, 2025, to December 3, 2028 [1] - The shares were pledged to Shandong International Trust in October 2024 for a two-year period [1] - The freezing was initiated by Shandong International Trust due to triggering early redemption clauses, leading to a court application for the freeze [1] Group 2 - Hainan Huluwawa Investment is currently in communication with various parties to resolve the issue promptly [1]

证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-088 海南葫芦娃药业集团股份有限公司 关于控股股东部分股份被司法冻结的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 公司控股股东海南葫芦娃投资发展有限公司（以下简称"葫芦娃投资"）持 有公司 167,079,000 股，占公司总股本 41.76%，葫芦娃投资持有公司的部分股份被 司法冻结 23,900,000 股，占其持股 14.30%，占公司总股本 5.97%。冻结期限由 2025 年 12 月 5 日至 2028 年 12 月 3 日。 （二）股东股份累计被冻结情况 截至本公告披露日，公司控股股东及其一致行动人累计被冻结股份情况如下： 一、股份被冻结情况 1 （一）本次股份被冻结基本情况 股东名称 冻结股 份数量 （股） 占其所 持股份 比例 （%） 占公司 总股本 比例 （%） 冻结/标 记股份是 否为限售 股 冻结/ 标记 起始日 冻结/ 标记 到期日 冻结 申请人 冻结 原因 海南葫芦 娃投资发 展有限公 23,900 ,0 ...

ST葫芦娃公告，公司控股股东海南葫芦娃投资发展有限公司持有公司1.67亿股，占公司总股本41.76%， 葫芦娃投资持有公司的部分股份被司法冻结2390万股，占其持股14.30%，占公司总股本5.97%。冻结期 限由2025年12月5日至2028年12月3日。 ...

Core Insights - The conference focused on the theme "Green Manufacturing, Dual Carbon Leadership, and Intelligent Future," aiming to explore new paths for the transformation and upgrading of the cookware industry [1] Group 1: Leadership Addresses - The Deputy Mayor of Chongming District, Xu Huiquan, highlighted the importance of light industrial kitchenware in Chongming's advanced manufacturing system and invited entrepreneurs to collaborate in talent cultivation and technological innovation [3] - Huang Yong, General Manager of Shanghai Guanhua Stainless Steel Products Co., emphasized the significance of green manufacturing and the need for industry consensus during the transformation period [5] - Guo Meide, President of Beijing Aowei Cloud Network, noted the industry's shift from functional satisfaction to experiential upgrades, driven by health concepts and policy guidance [7][8] Group 2: Industry Insights and Trends - Bi Zhitao, Director of the China Daily Hardware Technology Development Center, stated that the cookware industry has reached a scale of one trillion yuan and is at a critical juncture for green and digital transformation [10] - Jin Lixin, Vice President of the China Hardware Products Association, reported that the industry output value for 2023 is 100.51 billion yuan, with exports in the first three quarters of 2025 reaching 10.383 billion USD, a year-on-year increase of 1.09% [13] - Yu Ying, an industry researcher, projected the industry output value to reach 104.7 billion yuan in 2024, with a growth rate of 4%, and highlighted the challenges of high labor costs and market homogenization [15] Group 3: Corporate Practices and Innovations - Chen Helin, Chairman of Aishida Co., shared insights on the industry's evolution from "Made in China" to "Intelligent Manufacturing," urging companies to focus on innovation and quality standards [22] - Wang Zhenhua, General Manager of Zhejiang Supor Co., analyzed market trends and emphasized the need for differentiated innovation to meet new consumer demands [24] - Huang Huafeng, Chairman of Shanghai Guanhua, discussed the importance of integrating environmental concepts into the entire production process for sustainable development [27] Group 4: Technological Empowerment - Shan Zhihua, Deputy Secretary-General of the National Standardization Technical Committee, introduced the development of various national and industry standards to support the cookware sector [29] - Shang Guiqin, a member of the Food Safety National Standard Review Committee, emphasized the importance of compliance management for food contact materials [31] - Wang Yuru, from Gansu Jiuquan Steel Group, highlighted the innovative applications of 400 series stainless steel in the cookware industry, focusing on antibacterial and environmentally friendly materials [34] Group 5: Conclusion and Future Directions - Zhang Dongli, Chairman of the China Hardware Products Association, recommended that companies strengthen their domestic market presence while exploring emerging overseas markets in Southeast Asia and the Middle East [39] - The conference concluded with a call for collaboration among industry associations, manufacturers, and testing institutions to foster a healthy market ecosystem and seize future development opportunities [40]

每经头条（nbdtoutiao）——5年期大面积下线，3年期利率低至1.5%仍一单难求：要么"售罄"要么"额度 紧张"！中长期大额存单为何在消失？ （记者 曾健辉） 每经AI快讯，ST葫芦娃（SH 605199，收盘价：9.26元）12月1日晚间发布公告称，截至公告披露日，公 司及其控股子公司不存在对合并报表外单位提供担保的情况，公司累计为控股子公司担保余额约为3.13 亿元，占公司最近一期经审计净资产44.73%，无逾期担保情况。 2024年1至12月份，ST葫芦娃的营业收入构成为：医药制造业占比100.0%。 截至发稿，ST葫芦娃市值为37亿元。 ...

证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-087 海南葫芦娃药业集团股份有限公司 关于为全资子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | | | 被担保人名称 本次担保金额 | 3,050 | 广西维威制药有限公司 万元 | | | --- | --- | --- | --- | --- | --- | | 担 保 | 对 | | | | | | 象 | | 实际为其提供的担保余额 | 21,846.34 | 万元 | | | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | | 本次担保是否有反担保 | □是 | 否 | □不适用：_________ | 担保对象及基本情况 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 子公司对外担保总额（万元） | 31,333.74(不含本次) | | 对外担保总额占上市公司最近一 期经审计净资 ...

证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-086 重要内容提示： ● 海南葫芦娃药业集团股份有限公司（以下简称"公司"）2024年度内部控制被 出具否定意见审计报告，根据《上海证券交易所股票上市规则》第9.8.1条规定，公司 股票于2025年4月30日起被实施其他风险警示。 ● 根据《上海证券交易所股票上市规则》第9.8.5条："上市公司股票因第9.8.1 条第一款第（二）项至第（五）项规定情形被实施其他风险警示的，在被实施其他风险 警示期间，公司应当至少每月披露1次提示性公告，分阶段披露涉及事项的解决进展情 况"。公司将每月披露一次其他风险警示相关事项的进展情况，提示相关风险。 一、关于公司被实施其他风险警示的基本情况 因公司 2024 年度内部控制被立信会计师事务所（特殊普通合伙）出具了否定意 见的《内部控制审计报告》，根据《上海证券交易所股票上市规则》第 9.8.1 条第（三） 项规定的"最近一个会计年度财务报告内部控制被出具无法表示意见或否定意见的审计 报告，或未按照规定披露财务报告内部控制审计报告"的情形，公司股票自 2025 年 4 月 30 日起被实施其他风险警示。具体 ...